JP2013500267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500267A5 JP2013500267A5 JP2012521845A JP2012521845A JP2013500267A5 JP 2013500267 A5 JP2013500267 A5 JP 2013500267A5 JP 2012521845 A JP2012521845 A JP 2012521845A JP 2012521845 A JP2012521845 A JP 2012521845A JP 2013500267 A5 JP2013500267 A5 JP 2013500267A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- compound
- pyridinyl
- optionally substituted
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 2-pyridinyl Chemical group 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 40
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 7
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims 7
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 claims 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 7
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 claims 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims 7
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 150000004820 halides Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 230000004064 dysfunction Effects 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 108010005456 AMPA 4 glutamate receptor ionotropic Proteins 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 102100030668 Glutamate receptor 4 Human genes 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 241001377010 Pila Species 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 230000000848 glutamatergic effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 0 **S(CC1=CC=C2N(*)C(*)=NC2C1)(=O)=O Chemical compound **S(CC1=CC=C2N(*)C(*)=NC2C1)(=O)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22813709P | 2009-07-23 | 2009-07-23 | |
| US61/228,137 | 2009-07-23 | ||
| PCT/US2010/043110 WO2011011722A1 (en) | 2009-07-23 | 2010-07-23 | Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013500267A JP2013500267A (ja) | 2013-01-07 |
| JP2013500267A5 true JP2013500267A5 (enExample) | 2013-09-05 |
Family
ID=43499440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012521845A Withdrawn JP2013500267A (ja) | 2009-07-23 | 2010-07-23 | ｍＧＬｕＲ４増強剤としての置換されたベンゾイミダゾールスルホンアミド類および置換されたインドールスルホンアミド類 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120184556A1 (enExample) |
| EP (1) | EP2456310A4 (enExample) |
| JP (1) | JP2013500267A (enExample) |
| AU (1) | AU2010275477A1 (enExample) |
| BR (1) | BR112012001532A2 (enExample) |
| CA (1) | CA2768832A1 (enExample) |
| SG (1) | SG177740A1 (enExample) |
| WO (1) | WO2011011722A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010088406A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2464232B1 (en) | 2009-08-10 | 2015-10-07 | Samumed, LLC | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| SMT201700581T1 (it) | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| AU2012308570B2 (en) | 2011-09-14 | 2016-11-10 | Samumed, Llc | Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors |
| ES2604958T3 (es) | 2011-10-28 | 2017-03-10 | Vanderbilt University | Análogos de 2-(4-heterociclilbencil)isoindolin-1-ona sustituidos como moduladores alostéricos positivos del receptor muscarínico de acetilcolina M1 |
| US9073935B2 (en) | 2011-11-11 | 2015-07-07 | Vanderbilt University | Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
| US9029563B2 (en) | 2012-01-06 | 2015-05-12 | Vanderbilt University | Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine M1 receptors |
| WO2013106795A1 (en) | 2012-01-12 | 2013-07-18 | Vanderbilt University | Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors |
| PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| ME03573B (me) | 2012-05-04 | 2020-07-20 | Samumed Llc | 1H-PIRAZOLO[3,4-B]PIRIDINI l NJIHOVA TERAPEUTSKA UPOTREBA |
| CN105120862A (zh) | 2013-01-08 | 2015-12-02 | 萨穆梅德有限公司 | Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用 |
| EP2853532B1 (en) | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| CA2951784C (en) | 2014-06-10 | 2022-05-31 | Ube Industries, Ltd. | N-substituted sulfonamide compound and method for producing same |
| US10774072B2 (en) | 2014-06-10 | 2020-09-15 | Ube Industries, Ltd. | Crystal of N-substituted sulfonamide compound |
| JP6572890B2 (ja) * | 2014-06-10 | 2019-09-11 | 宇部興産株式会社 | ヘテロ芳香族スルホンアミド化合物の製造方法 |
| WO2016040182A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof |
| WO2016040188A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040184A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040185A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof |
| WO2016040190A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040193A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof |
| WO2016040180A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016040181A1 (en) | 2014-09-08 | 2016-03-17 | Samumed, Llc | 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof |
| WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2017024026A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| US10519169B2 (en) | 2015-08-03 | 2019-12-31 | Samumed, Llc | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10383861B2 (en) | 2015-08-03 | 2019-08-20 | Sammumed, LLC | 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10226448B2 (en) | 2015-08-03 | 2019-03-12 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof |
| WO2017023989A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10195185B2 (en) | 2015-08-03 | 2019-02-05 | Samumed, Llc | 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof |
| US10350199B2 (en) | 2015-08-03 | 2019-07-16 | Samumed, Llc | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof |
| WO2017023980A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof |
| WO2017024004A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024003A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc | 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10206908B2 (en) | 2015-08-03 | 2019-02-19 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof |
| US10463651B2 (en) | 2015-08-03 | 2019-11-05 | Samumed, Llc | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof |
| WO2017023988A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017023993A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| WO2017024015A1 (en) | 2015-08-03 | 2017-02-09 | Samumed, Llc. | 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof |
| US10604512B2 (en) | 2015-08-03 | 2020-03-31 | Samumed, Llc | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof |
| US10285983B2 (en) | 2015-08-03 | 2019-05-14 | Samumed, Llc | 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof |
| CN108473491A (zh) | 2015-11-06 | 2018-08-31 | 萨穆梅德有限公司 | 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途 |
| AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| DK3464285T3 (da) | 2016-06-01 | 2022-12-19 | Biosplice Therapeutics Inc | Fremgangsmåde til fremstilling af n-(5-(3-(7-(3-fluorphenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamid |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP3528808B1 (en) | 2016-10-21 | 2021-10-06 | BioSplice Therapeutics, Inc. | Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors |
| MA46696A (fr) | 2016-11-07 | 2019-09-11 | Samumed Llc | Formulations injectables à dose unique prêtes à l'emploi |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| PE20200756A1 (es) | 2017-08-16 | 2020-07-27 | Univ Vanderbilt | Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica |
| US12274703B2 (en) | 2017-12-21 | 2025-04-15 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
| JP2021507945A (ja) * | 2017-12-21 | 2021-02-25 | グリアファーム エスエー | 認知症を含む神経障害のための組成物および治療方法 |
| US12310967B2 (en) | 2017-12-21 | 2025-05-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| EP3728200A1 (en) * | 2017-12-21 | 2020-10-28 | Gliapharm SA | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| WO2020132378A2 (en) * | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
| US10836752B1 (en) | 2020-04-02 | 2020-11-17 | Qatar University | Method for synthesizing 1-(naphthalen-2-ylsulfonyl)-3-(thiophen-2-yl) diaziridine |
| AU2024267789A1 (en) * | 2023-05-11 | 2025-11-13 | The Trustees Of The University Of Pennsylvania | Heterocyclic compounds for imaging aggregated tau in tauopathies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH632628B (de) * | 1976-07-26 | Ciba Geigy Ag | Verfahren zur herstellung von benzofuranyl-benzimidazolen und deren verwendung als optische aufheller. | |
| LU76819A1 (enExample) * | 1977-02-22 | 1978-10-18 | ||
| EP0010063B1 (de) * | 1978-10-04 | 1982-12-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von Furanyl-benzazolen |
| US7329679B2 (en) * | 2000-01-27 | 2008-02-12 | Schering Aktiengesellschaft | 1,2 Diarylbenzimidazoles and their pharmaceutical use |
| US6608176B2 (en) * | 2000-03-31 | 2003-08-19 | University Of Miami | Taste receptor for umami (monosodium glutamate) taste |
| WO2002022579A2 (en) * | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
| US7169788B2 (en) * | 2001-10-30 | 2007-01-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20060166972A1 (en) * | 2003-07-11 | 2006-07-27 | Conn P J | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
| EP1855670A4 (en) * | 2005-02-24 | 2010-05-05 | Merck Sharp & Dohme | BENZAZOLE AMPLIFIERS OF METABOTROPIC GLUTAMATE RECEPTORS |
| TW200808769A (en) * | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
| PE20080888A1 (es) * | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
| US8759345B2 (en) * | 2008-04-28 | 2014-06-24 | Janssen Pharmaceutica Nv | Benzoimidazoles as prolyl hydroxylase inhibitors |
-
2010
- 2010-07-23 JP JP2012521845A patent/JP2013500267A/ja not_active Withdrawn
- 2010-07-23 CA CA2768832A patent/CA2768832A1/en not_active Abandoned
- 2010-07-23 AU AU2010275477A patent/AU2010275477A1/en not_active Abandoned
- 2010-07-23 BR BR112012001532A patent/BR112012001532A2/pt not_active IP Right Cessation
- 2010-07-23 WO PCT/US2010/043110 patent/WO2011011722A1/en not_active Ceased
- 2010-07-23 SG SG2012005047A patent/SG177740A1/en unknown
- 2010-07-23 US US13/386,651 patent/US20120184556A1/en not_active Abandoned
- 2010-07-23 EP EP10802979A patent/EP2456310A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2785713B1 (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | |
| JP2013500267A (ja) | ｍＧＬｕＲ４増強剤としての置換されたベンゾイミダゾールスルホンアミド類および置換されたインドールスルホンアミド類 | |
| JP5883399B2 (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのピラゾロピリジン、ピラゾロピラジン、ピラゾロピリミジン、ピラゾロチオフェンおよびピラゾロチアゾール化合物、組成物、および神経機能不全を治療する方法 | |
| JP2013526544A (ja) | 複素環スルホンｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 | |
| TW200840573A (en) | Heterocyclic compounds and their methods of use | |
| JP2013526544A5 (enExample) | ||
| JP2013508412A (ja) | ｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 | |
| JP2013510178A (ja) | ｍＧｌｕＲ４アロステリック増強剤としてのアリールおよびヘテロアリールスルホン、組成物、および神経機能不全を治療する方法 | |
| BR112016016432B1 (pt) | N-heteroarilas substituídas por n-azaspirocicloalcano, seus usos, e composição farmacêutica | |
| JP2013503909A (ja) | ｍＧＬｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 | |
| JP2012516355A (ja) | ｍＧＬｕＲ４アロステリック増強剤としての置換された１，１，３，３−テトラオキシドベンゾ［ｄ］［１，３，２］ジチアゾール、組成物、および神経機能不全を治療する方法 | |
| JP2008189659A5 (enExample) | ||
| US12043607B2 (en) | HDAC inhibitors and therapeutic use thereof | |
| KR20170032468A (ko) | 간 x 수용체 조정제로서 피페라진 유도체 | |
| WO2023146897A1 (en) | 2-substituted thiazole hsd17b13 inhibitors and uses thereof | |
| JP2016537360A (ja) | 神経変性疾患を治療するための新規な方法 | |
| CA2744929C (en) | Methods of treating alpha adrenergic mediated conditions | |
| US8242103B2 (en) | Sulphamides for treatment of cancer | |
| WO2022226161A1 (en) | Glun2 subunit selective antagonists of the n-methyl-d-aspartate receptors | |
| AU2021302681A1 (en) | Novel compounds |